Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are absent from the provided label content (including Lipitor cognitive impairment and numerous cross-drug potency/side-effect/indication/cost/generic assertions), creating substantial alignment gaps with the supplied FDA label sections.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Supported by 12.1 Mechanism of Action (HMG-CoA reductase inhibition/cholesterol synthesis and cholesterol/lipoprotein lowering described).
Lipitor works by inhibiting the production of cholesterol in the liver.
Supported by 12.1 Mechanism of Action (inhibits HMG-CoA reductase; cholesterol synthesis in the liver).
Lipitor reduces low-density lipoprotein (LDL) cholesterol levels in the blood.
Supported by 12.1 Mechanism of Action (reduces LDL-C and related fractions/particles).
Possible side effects of Lipitor include muscle pain.
Supported by 5.1 Skeletal Muscle (myopathy defined as muscle aches or muscle weakness; report muscle pain/tenderness/weakness).
Unsupported Statements
Possible side effects of Lipitor include cognitive impairment.
Absent from the provided label sections; not supported by 5.4 CNS Toxicity in the supplied text.
Simvastatin (Zocor) is similar to Lipitor.
Cross-drug comparative statement with no supporting content in the provided label sections.
Simvastatin is available in generic form.
Generic availability is not supported by the provided label sections.
Pravastatin (Pravachol) is a statin medication prescribed as an alternative to Lipitor.
Alternative/therapeutic substitution framing is not supported by the provided label sections for Lipitor.
Pravastatin is known for a lower risk of muscle damage.
Relative safety comparison is not supported by the provided label sections.
Pravastatin is known for a lower risk of liver toxicity.
Relative safety comparison is not supported by the provided label sections.
Rosuvastatin (Crestor) is a more potent statin medication than Lipitor.
Potency comparison is not supported by the provided label sections.
Rosuvastatin is prescribed for individuals with high cholesterol or heart disease.
Rosuvastatin indication framing is not supported by the provided label sections.
Rosuvastatin is more expensive than Lipitor.
Cost comparison is not supported by the provided label sections.
Rosuvastatin is more effective in reducing LDL cholesterol levels than Lipitor.
Comparative efficacy superiority is not supported by the provided label sections.
Fluvastatin (Lescol) is a less potent statin medication than Lipitor.
Potency comparison is not supported by the provided label sections.
Fluvastatin is prescribed for individuals with mild to moderate high cholesterol.
Indication framing for fluvastatin is not supported by the provided label sections.
Fluvastatin is known for a lower risk of side effects.
Relative safety comparison is not supported by the provided label sections.
Fluvastatin is available in generic form.
Generic availability is not supported by the provided label sections.
Bile acid sequestrants (Questran, LoCholest) bind to bile acids in the gut.
Mechanism statement is not supported by the provided label sections.
Bile acid sequestrants (Questran, LoCholest) reduce the amount of cholesterol produced in the liver.
Mechanistic statement is not supported by the provided label sections.
Fibrates (Tricor, Lopid) reduce triglyceride levels.
Cross-drug class mechanism/efficacy statement not supported by provided label sections.
Fibrates (Tricor, Lopid) increase HDL cholesterol levels.
Cross-drug class mechanism/efficacy statement not supported by provided label sections.
Cholesterol absorption inhibitors (Zetia) reduce the amount of cholesterol absorbed from the diet.
Cross-drug class mechanism statement not supported by provided label sections.
Contradictions
Important Omissions
For the stated contraindication, the label text specifies 'Active liver disease' (may include unexplained persistent elevations in hepatic transaminase levels) as contraindication; the claim 'contraindicated in individuals with liver disease' is broader than the label wording and would benefit from label-specific phrasing tied to 'active liver disease' criteria.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The inclusion of an unsupported Lipitor safety claim (cognitive impairment) and multiple unsupported cross-drug comparative claims could mislead users about Lipitor’s adverse effects and alternatives. A broad liver-disease contraindication phrasing also reduces label precision.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported/absent-from-label claims (notably Lipitor cognitive impairment) and extensive cross-drug comparison/class mechanism statements without label support.
Suggested Improvement
Remove or strictly revise any Lipitor adverse effect statements to those explicitly supported by the provided label sections (e.g., 5.1/5.2). Omit cross-drug comparisons (potency, effectiveness, relative safety, indications, generic availability, cost, and class mechanism statements) unless the provided FDA label text for those specific products/sections is included and cited.